Suppr超能文献

极低风险肾母细胞瘤亚组表现出独特的基因表达、组织学和临床特征。

Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.

机构信息

Departments of Pathology and Preventive Medicine, Northwestern University Feinberg School of Medicine and Robert H. Lurie Cancer Center, Chicago, Illinois, USA.

出版信息

Clin Cancer Res. 2009 Nov 15;15(22):6800-9. doi: 10.1158/1078-0432.CCR-09-0312. Epub 2009 Nov 10.

Abstract

PURPOSE

Recent studies suggest that children <24 months with stage I favorable histology Wilms tumors <550 g [very low risk Wilms tumors (VLRWT)] have an excellent prognosis when treated with nephrectomy only, without adjuvant chemotherapy. The identification of risk categories within VLRWT may enable refinement of their definition and optimization of their therapy.

EXPERIMENTAL DESIGN

To define biologically distinct subsets, global gene expression analysis was done on 39 VLRWT that passed all quality-control parameters and the clusters identified were validated in an independent set of 11 VLRWT. Validation of select differentially expressed genes was done with immunohistochemistry on a tissue microarray from 20 of 39 tumors. Loss of heterozygosity (LOH) for 11p15, 1p, and 16q was analyzed in 52 tumors using PCR.

RESULTS

Two distinctive clusters were identified. One cluster included 9 tumors with epithelial differentiated tubular histology, paucity of nephrogenic rests, lack of LOH for 1p, 16q, and 11p, absence of relapse, and a unique gene expression profile consistent with arrest following mesenchymal-to-epithelial transition. The second cluster included 13 tumors with mixed histology, intralobar nephrogenic rests, and decreased expression of WT1. Three of 6 relapses occurred in this cluster. Of 43 informative tumors, 11p LOH was present in 5 of 5 relapses and 11 of 38 nonrelapses.

CONCLUSIONS

Two subsets comprising a total of 56% of VLRWT are identified that have pathogenetic and molecular differences and apparent differences in risk for relapse. If these predictors can be prospectively validated, this would enable the refinement of clinical stratification and less arbitrary definition of VLRWT.

摘要

目的

最近的研究表明,对于 24 个月以下、肿瘤组织学 I 期且瘤重<550g(极低危威尔姆斯瘤(VLRWT))的患儿,仅行肾切除术而不接受辅助化疗即可获得极佳的预后。VLRWT 中危险类别的确定可能有助于明确其定义,并优化其治疗方案。

实验设计

为了确定具有生物学差异的亚群,对 39 例通过所有质量控制参数的 VLRWT 进行了全基因组基因表达分析,并在一组 11 例 VLRWT 中对鉴定出的聚类进行了验证。在 20 例肿瘤的组织微阵列上使用免疫组织化学法对选定的差异表达基因进行了验证。利用 PCR 分析了 52 例肿瘤中 11p15、1p 和 16q 的杂合性缺失(LOH)情况。

结果

鉴定出两个截然不同的聚类。一个聚类包括 9 例具有上皮分化的管状组织学特征、肾胚细胞瘤稀少、1p、16q 和 11p 缺失 LOH、无复发以及与间充质向上皮转化后停滞相关的独特基因表达谱的肿瘤。第二个聚类包括 13 例具有混合组织学特征、叶内肾胚细胞瘤和 WT1 表达减少的肿瘤。6 例复发中有 3 例发生在该聚类中。在 43 例可评估的肿瘤中,11p LOH 存在于 5 例复发肿瘤和 11 例非复发肿瘤中。

结论

确定了两种共占 VLRWT 总数 56%的亚群,它们具有发病机制和分子上的差异,以及复发风险的明显差异。如果这些预测指标能够前瞻性验证,将有助于完善临床分层,减少对 VLRWT 的任意定义。

相似文献

1
Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.
Clin Cancer Res. 2009 Nov 15;15(22):6800-9. doi: 10.1158/1078-0432.CCR-09-0312. Epub 2009 Nov 10.
3
Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Am J Pathol. 1998 Sep;153(3):991-1000. doi: 10.1016/S0002-9440(10)65641-6.
5
Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Med Pediatr Oncol. 1996 Nov;27(5):429-33. doi: 10.1002/(SICI)1096-911X(199611)27:5<429::AID-MPO7>3.0.CO;2-O.

引用本文的文献

1
Loss of heterozygosity for chromosomes 16q in Wilms tumors predicts outcomes: A meta-analysis.
World J Gastrointest Oncol. 2024 May 15;16(5):2159-2167. doi: 10.4251/wjgo.v16.i5.2159.
2
Hallmark discoveries in the biology of Wilms tumour.
Nat Rev Urol. 2024 Mar;21(3):158-180. doi: 10.1038/s41585-023-00824-0. Epub 2023 Oct 17.
5
Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.
J Natl Compr Canc Netw. 2021 Aug 1;19(8):978-985. doi: 10.6004/jnccn.2021.7070.
7
Development and validation of a nomogram for predicting cancer-specific survival in patients with Wilms' tumor.
J Cancer. 2019 Aug 28;10(21):5299-5305. doi: 10.7150/jca.32741. eCollection 2019.
8
Pharmacotherapeutic Management of Wilms Tumor: An Update.
Paediatr Drugs. 2019 Feb;21(1):1-13. doi: 10.1007/s40272-018-0323-z.
9
Geometry of Gene Expression Space of Wilms' Tumors From Human Patients.
Neoplasia. 2018 Aug;20(8):871-881. doi: 10.1016/j.neo.2018.06.006. Epub 2018 Jul 18.
10
Germline mutations and somatic inactivation of TRIM28 in Wilms tumour.
PLoS Genet. 2018 Jun 18;14(6):e1007399. doi: 10.1371/journal.pgen.1007399. eCollection 2018 Jun.

本文引用的文献

2
Atlas of gene expression in the developing kidney at microanatomic resolution.
Dev Cell. 2008 Nov;15(5):781-91. doi: 10.1016/j.devcel.2008.09.007.
3
The role of insulin receptors and IGF-I receptors in cancer and other diseases.
Arch Physiol Biochem. 2008 Feb;114(1):23-37. doi: 10.1080/13813450801969715.
4
DBC1 is a negative regulator of SIRT1.
Nature. 2008 Jan 31;451(7178):583-6. doi: 10.1038/nature06500.
6
The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer.
Curr Pharm Des. 2007;13(7):671-86. doi: 10.2174/138161207780249173.
8
Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney.
EMBO J. 2006 Nov 1;25(21):5214-28. doi: 10.1038/sj.emboj.7601381. Epub 2006 Oct 12.
10
Classification of malignant pediatric renal tumors by gene expression.
Pediatr Blood Cancer. 2006 Jun;46(7):728-38. doi: 10.1002/pbc.20773.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验